Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Samsung Biologics Co.,Ltd.
  6. Summary
    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
End-of-day quote Korea Stock Exchange  -  2022-09-28
813000.00 KRW   +6.00%
09/29Samsung Biologics Earns Gold Rating from EcoVadis for Its Sustainability Efforts
AQ
09/05S.Korean shares end at over six-week low on Europe energy worries
RE
08/18Samsung Biologics : Material Business Matters Related to Investment Decisions
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
09/23/2022 09/26/2022 09/27/2022 09/28/2022 09/29/2022 Date
770000 758000 754000 767000 813000 Last
44823 51357 52424 92653 179902 Volume
-1.91% -1.56% -0.53% +1.72% +6.00% Change
Estimated financial data (e)
Sales 2022 2 352 B 1,65 B 1,65 B
Net income 2022 604 B 0,42 B 0,42 B
Net cash position 2022 388 B 0,27 B 0,27 B
P/E ratio 2022 93,7x
Yield 2022 -
Sales 2023 2 830 B 1,98 B 1,98 B
Net income 2023 694 B 0,49 B 0,49 B
Net Debt 2023 22,6 B 0,02 B 0,02 B
P/E ratio 2023 82,3x
Yield 2023 -
Capitalization 57 864 B 40 471 M 40 471 M
EV / Sales 2022 24,4x
EV / Sales 2023 20,5x
Nbr of Employees 4 001
Free-Float 25,7%
More Financials
Company
Samsung Biologics Co Ltd is a Korea-based company primarily engaged in development, manufacture and distribution of biological products. The Company, as a contract manufacturing organization (CMO), mainly develops and manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. It also provides cell line development and process development services. The Company... 
Sector
Pharmaceuticals
Calendar
10/25Earnings Release
More about the company
Ratings of Samsung Biologics Co.,Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about SAMSUNG BIOLOGICS CO.,LTD.
09/29Samsung Biologics Earns Gold Rating from EcoVadis for Its Sustainability Efforts
AQ
09/05S.Korean shares end at over six-week low on Europe energy worries
RE
08/18Samsung Biologics : Material Business Matters Related to Investment Decisions
PU
08/16Samsung Biologics Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Mont..
CI
08/09Frost & Sullivan Institute Recognizes Samsung Biologics with the 2022 Global Enlightene..
AQ
08/09UBS Starts Samsung Biologics at Buy With 1,070,000 Won Price Target
MT
08/05S.Korean shares post third straight weekly gain
RE
08/01GreenLight Biosciences and Samsung Biologics Completes First Commercial-Scale Engineeri..
CI
07/28Samsung Biologics' Net Income Jumps 25.1% in June Quarter
MT
07/19Samsung Biologics to Add a Second Manufacturing Campus Near Seoul
MT
07/19Samsung Biologics : Decision on Acquisition of Tangible Assets
PU
06/27South Korean Stocks Rise for Second Day as Investors Speculate Fed Rate Hike Pace; Sams..
MT
06/27South Korea's Corporate Direct Financing Declines 3.5% in May
MT
05/25South Korea Indexes Close Higher on Gains by Chem, Bio Firms; Samsung Biologics Adds 3%
MT
05/25South Korean Stocks Close Higher on Chemical, Bio Stocks’ Gains
MT
More news
News in other languages on SAMSUNG BIOLOGICS CO.,LTD.
09/05Les actions sud-coréennes terminent à leur plus bas niveau depuis plus de six semaines ..
08/23MÄRKTE ASIEN/Aktien auf breiter Front talwärts
08/16Samsung Biologics Co.,Ltd. annonce ses résultats pour le deuxième trimestre et le semes..
08/05Les actions sud-coréennes affichent un troisième gain hebdomadaire consécutif
08/01GreenLight Biosciences et Samsung Biologics achèvent le premier cycle d'ingénierie à l'..
More news
Analyst Recommendations on SAMSUNG BIOLOGICS CO.,LTD.
More recommendations
ETFs positioned on SAMSUNG BIOLOGICS CO.,LTD.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
KraneShares Emerging Market Healthcare Inde...4.23%-0.66%NC
IShares MSCI South Korea ETF - USD1.78%-6.92%Korea
Franklin FTSE South Korea ETF - USD1.76%-7.07%South Korea
Xtrackers MSCI Korea 1C - USD1.6%-7.65%-NC
IShares MSCI Korea (Acc) - USD1.58%-7.72%-Korea
More ETFs positioned on SAMSUNG BIOLOGICS CO.,LTD.
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 813 000,00
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
John Chongbo Rim President, Chief Executive Officer & Director
Doyoung Heo Head-Finance & Vice President
Tae-Han Kim Chairman
Yong-Ho An Managing Director & Head-Process Technology
Hyung-Woo Moon Head-Compliance Support
Sector and Competitors
1st jan.Capi. (M$)
SAMSUNG BIOLOGICS CO.,LTD.-9.97%40 471
CSL LIMITED-1.37%89 594
BIOGEN INC.10.15%38 350
WUXI BIOLOGICS (CAYMAN) INC.-48.46%25 917
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-29.98%19 605
BIOMARIN PHARMACEUTICAL INC.-3.72%15 776